U.S. Healthcare Services Stock News

If you are wondering whether WEX at around US$159.95 is priced fairly or offering value, you are not alone. This article is built to help you assess that question using several valuation tools. The stock has been relatively mixed recently, with a 7.8% return year to date and 3.8% over the last year, alongside a 4.3% decline over the past week and a 1.4% gain over the last 30 days. These movements can change how the market is thinking about its risk and opportunity. Recent coverage has...

The National Transportation Safety Board plans to hold a hearing on Ford Motor's BlueCruise hands free driving system following two fatal crashes. The hearing will examine how the advanced driver assistance system was used in the incidents and whether additional safety measures are needed. The review puts Ford's automated driving technology and safety practices under closer regulatory and public scrutiny. For investors watching NYSE:F at a current share price of $11.67, this hearing comes...

LKQ stock performance context LKQ (LKQ) shares closed at $29.34, with the stock showing a 1 day return of 1.38% and a 7 day decline of 6.77%. This sets the stage for a closer look at its recent performance. See our latest analysis for LKQ. At the current share price of $29.34, LKQ’s 30 day share price return of a 13.96% decline sits alongside a 1 year total shareholder return of a 26.95% decline, pointing to fading momentum rather than a short term blip. If LKQ’s recent pullback has you...

Earlier this month, AT&T announced over US$250.00 billion of planned U.S. connectivity investment through 2030, launched more flexible Unlimited Your Way wireless plans, and issued long-dated Canadian dollar bonds to support its network build-out. Together, these moves highlight AT&T’s push to reposition itself as a core connectivity platform for AI-era data demand while sharpening its consumer value proposition. Now we’ll examine how AT&T’s US$250.00 billion connectivity build-out plan...

Why Celldex Therapeutics (CLDX) is on investors’ radar today Celldex Therapeutics (CLDX) has drawn attention after recent trading, with shares last closing at $29.51 and showing mixed returns over the past week, month, past 3 months, and year. See our latest analysis for Celldex Therapeutics. Recent trading has been choppy, with a 30 day share price return of 28.30% and a 1 year total shareholder return of 44.52%, set against a weaker 3 year total shareholder return of 29.47% and a 5 year...

Recent share performance and business snapshot Titan America (TTAM) has drawn attention after a one month return showing a 16.1% decline, extending a past 3 months slide of 7.8%. This has prompted investors to reassess the cement and building materials producer. The Brussels based company reports annual revenue of US$1.65b and net income of US$178.46m, with recent revenue growth of 6.3% and net income growth of 13.7%. This has put a spotlight on how earnings support the current share...

G-III Apparel Group has reported a weaker fourth quarter for fiscal 2026, with sales falling to US$771.49 million and a net loss of US$31.94 million, while also guiding to lower near-term revenue and earnings as it exits Calvin Klein and Tommy Hilfiger licenses and absorbs charges related to the Saks Global bankruptcy. Alongside these softer results, the company reaffirmed its portfolio shift toward higher-margin owned brands, announced a US$0.10 quarterly dividend, and outlined a US$25...

PENN Entertainment (PENN) is back on investors’ radar after announcing a 203-room hotel tower and an expanded high-limit table games room at Hollywood Casino Columbus, both pending regulatory approvals. See our latest analysis for PENN Entertainment. Despite the hotel and high limit room expansion plans and the recent earnings surprise in Q4 2025, sentiment around PENN has been mixed. A 21.68% 1 month share price return contrasts with a 16.27% 1 year total shareholder return decline and an...

IDEAYA Biosciences (IDYA) enrolled the first patient in its Phase 1 IDE892 trial for MTAP-deleted solid tumors and updated investors on its broader MTAP-deletion and CDKN2A-deficiency pipeline. The company also trimmed certain combination studies. See our latest analysis for IDEAYA Biosciences. The latest IDE892 trial update comes after a 1-month share price return of 9.32% and a 1-year total shareholder return of 78.09%, suggesting recent momentum on top of already strong longer term...

Earlier this month, Jones Lang LaSalle unveiled its Accelerate 2030 plan, pairing new long-term financial targets with an enlarged share repurchase authorization of US$4.40 billion, including a US$200 million accelerated buyback. This combination of technology-led growth ambitions and a very large capital return commitment marks a meaningful shift in how JLL is positioning itself for clients and shareholders through 2030. Next, we’ll consider how JLL’s significantly expanded share buyback...

Setting the scene on U.S. Physical Therapy With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income. See our latest analysis for U.S. Physical Therapy. The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return...

In early March 2026, AAON reported fourth-quarter 2025 results showing US$424.22 million in sales and full-year earnings per share of US$1.29, while also affirming a regular quarterly dividend of US$0.10 per share payable on March 30, 2026. At the same time, AAON highlighted its Alpha Class EXTREME SERIES rooftop unit’s success in the U.S. Department of Energy’s HVAC Technology Challenge, underlining how advanced dual-fuel heat pump capability and cold-weather performance could reinforce...

Wix.com Ltd. recently reported its fourth-quarter 2025 results, showing revenue of US$524.27 million and a net loss of US$40.23 million, alongside full-year 2025 revenue of US$1.99 billion and net income of US$50.65 million. On the same day, Wix.com issued mid-teens percentage revenue growth guidance for both the first quarter and full year 2026 and secured a US$250,000,000 private placement featuring warrants and lock-up agreements with Durable Capital Partners and other investors,...

In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine. This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion...

Earlier in March, Federated Hermes announced that four of its investment strategies received LSEG Lipper Fund Awards 2026 US for consistently strong risk‑adjusted performance, while CEO J. Christopher Donahue is scheduled to present at the RBC Capital Markets Global Financial Institutions Conference 2026 in New York on March 11. This combination of third‑party recognition and high recent earnings growth and return on equity is sharpening attention on how effectively Federated Hermes converts...

In early March 2026, Clarivate Plc announced it had integrated its Cortellis Regulatory Intelligence data with Anthropic’s Claude via the open Model Context Protocol, giving biopharma, biotech, medtech and clinical research organizations context-aware access to authoritative regulatory data directly within their existing AI workflows. This move highlights how Clarivate is aiming to embed its validated regulatory content deeper into customers’ day-to-day decision processes, potentially...

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...

Seagate Technology Holdings (STX) is back in focus after its Mozaic 4+ heat assisted magnetic recording platform moved from announcement to volume production with two hyperscale cloud providers, directly tied to AI driven storage demand. See our latest analysis for Seagate Technology Holdings. The latest Mozaic 4+ deployment arrives after a sharp run in Seagate’s share price, with a 90 day share price return of 34.36% and a year to date share price return of 33.45%, even after a 30 day share...

Hershey (HSY) is back in focus after an upgrade to Zacks Rank #1, following strong Q4 results and ambitious 2026 forecasts that sit alongside fresh launches like Dot's Original Snack Mix and new Twizzlers Straws. See our latest analysis for Hershey. At a share price of $217.09, Hershey has a 90 day share price return of 15.41% and a 1 year total shareholder return of 31.45%. This suggests momentum has picked up recently, even after a softer 7 day share price return of 3.51% and ongoing cost...

EHang Holdings Limited reported its fourth-quarter 2025 results on March 12, 2026, with sales rising to CNY 243.78 million and quarterly net income reaching CNY 10.49 million, while full-year 2025 revenue increased to CNY 509.50 million alongside a full-year net loss of CNY 230.54 million. The shift from a quarterly net loss in the prior year to profitability in Q4 2025, even as the full year remained loss-making, highlights a meaningful improvement in operating performance and cost...

Why Evercore (EVR) is on investors’ radar today Evercore (EVR) has drawn fresh attention after a period of mixed share performance, with a recent 0.4% daily gain that contrasts with weaker moves over the past week, month, and past 3 months. See our latest analysis for Evercore. That 0.4% 1 day share price gain comes after a tougher spell, with a 7.2% 7 day share price decline and a 23.6% year to date share price decline, even though the 1 year total shareholder return is 35.1% and the 3 year...

Wynn Resorts has resumed construction on its US$5.10 billion Wynn Al Marjan Island integrated resort in Ras Al Khaimah, UAE, after a brief security-related pause, while maintaining close coordination with US and UAE authorities to safeguard employees and operations. This restart reinforces Wynn’s push into the Middle East through a 40% stake in the project, marking the region’s first large-scale casino resort and expanding its luxury hospitality footprint beyond existing US and Asia...

If you are wondering whether Enova International at around US$134.11 is still offering value or already pricing in a lot of optimism, you are asking the right question for this stock. The share price has seen a 2.5% decline over the last 7 days and a 10.1% decline over the last 30 days, although the 1 year return sits at 44.8% and the 3 year return is 220.5%, with 5 year returns at 266.4%. Recent coverage of Enova International has focused on its position within the diversified financials...

On Holding (NYSE:ONON) is back in focus after releasing its 2025 results and outlining 2026 guidance, with management expecting at least 23% constant currency net sales growth to a minimum CHF 3.44b. See our latest analysis for On Holding. The latest guidance and 2025 numbers arrive after a softer patch for the shares. The 30 day share price return is 16.12%, and the year to date share price return is a 19.08% decline. However, the 3 year total shareholder return of 75.80% shows that longer...